Interview with Reinhard Uppenkamp, Chairman, Berlin Chemie/Menarini
When we met Dr. Aleiotti in Italy, he said how important was Menarini´s acquisition of Berlin Chemie in the 1990s for the internationalization of the company in Eastern Europe and…
Address: An der Wiek 7, 17493 Greifswald – Insel Riems,Germany
Tel: +49 38351 76-0
RIEMSER Arzneimittel AG is a company with tradition and a future.Following its demerger from the Friedrich-Loeffler-Institute Riems Island (FLI), RIEMSER Arzneimittel AG has, within a period of just a few years, evolved to become one of East Germany’s largest producers and developers of pharmaceutical products.RIEMSER has affiliated branches in such German Federal States such as Saarland, Baden-Württemberg, and Saxony as well as abroad. The company has more than 618 employees at various locations. In 2008, the group achieved sales of the order of 85,4 million euros. RIEMSER exports to more than 80 countries, including China, Russia and the U.S.A. Business transacted abroad will grow to more than 40 percent of total sales in fiscal 2009. The company prides itself on a well-diversified portfolio, which encompasses the areas human, veterinary, and dental. Its core competencies focus on oncology and dermatology as well as on dental products and anti-infectives, in veterinary, the emphasis is on animal vaccines.
When we met Dr. Aleiotti in Italy, he said how important was Menarini´s acquisition of Berlin Chemie in the 1990s for the internationalization of the company in Eastern Europe and…
With a wide experience in other international pharmaceutical companies, what attracted you to come to Bausch&Lomb, the ophthalmology pharma company? Bausch&Lomb offered me a unique set of challenges and possibilities…
Gilead was founded in 1987 and only four years later it established itself in the German market. Since then the company has become internationally known for breakthroughs that resulted in…
As part of the PKV – the German Association of Private Health Insurance – could you briefly introduce to our readers the German private health care system and its main…
Could you briefly introduce our readers the how the GPHF managed to improve health care in developing countries since its foundation in 1987? The former abbreviation of GPHF stood for…
You have been leading GSK, one of the top five pharmaceutical companies in the German market, for just over a year, after having worked previously in Poland, the UK, France,…
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Hospira, which was spun-off from Abbott Laboratories in 2004, is a global specialty pharmaceutical and medication delivery company driven by its vision of Advancing Wellness™. Bringing proven leadership and experience,…
How challenging is for you as General Manager of Nycomed Germany to lead the number one subsidiary of the Nycomed Group and what would you highlight as the key milestones…
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
See our Cookie Privacy Policy Here
